JP7320898B1 - Fragile X mental retardation, autosomal homolog 2遺伝子発現亢進用医薬組成物及び食品組成物 - Google Patents
Fragile X mental retardation, autosomal homolog 2遺伝子発現亢進用医薬組成物及び食品組成物 Download PDFInfo
- Publication number
- JP7320898B1 JP7320898B1 JP2023088851A JP2023088851A JP7320898B1 JP 7320898 B1 JP7320898 B1 JP 7320898B1 JP 2023088851 A JP2023088851 A JP 2023088851A JP 2023088851 A JP2023088851 A JP 2023088851A JP 7320898 B1 JP7320898 B1 JP 7320898B1
- Authority
- JP
- Japan
- Prior art keywords
- enhancing
- gene expression
- fragile
- food
- mental retardation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000014509 gene expression Effects 0.000 title claims abstract description 29
- 230000002708 enhancing effect Effects 0.000 title claims abstract description 25
- 235000013305 food Nutrition 0.000 title claims abstract description 25
- 239000000203 mixture Substances 0.000 title claims abstract description 14
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 14
- 101150028074 2 gene Proteins 0.000 title claims abstract 5
- 208000036626 Mental retardation Diseases 0.000 title claims abstract 5
- FIFRJJLOOYYYOZ-UHFFFAOYSA-N 5-acetyl-1-benzylpyrrolidin-2-one Chemical compound CC(=O)C1CCC(=O)N1CC1=CC=CC=C1 FIFRJJLOOYYYOZ-UHFFFAOYSA-N 0.000 claims abstract description 16
- 239000004480 active ingredient Substances 0.000 claims abstract description 7
- 230000001737 promoting effect Effects 0.000 claims description 3
- 102100036336 Fragile X mental retardation syndrome-related protein 2 Human genes 0.000 abstract description 14
- 101000930952 Homo sapiens Fragile X mental retardation syndrome-related protein 2 Proteins 0.000 abstract description 14
- 101100335685 Homo sapiens FXR2 gene Proteins 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 12
- 239000000843 powder Substances 0.000 description 10
- 239000002775 capsule Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- -1 etc.) Substances 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- 229920002472 Starch Polymers 0.000 description 7
- 239000008107 starch Substances 0.000 description 7
- 235000019698 starch Nutrition 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 235000000346 sugar Nutrition 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Natural products C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 238000000018 DNA microarray Methods 0.000 description 4
- 239000006057 Non-nutritive feed additive Substances 0.000 description 4
- 240000008042 Zea mays Species 0.000 description 4
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 4
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 239000006143 cell culture medium Substances 0.000 description 4
- 239000007910 chewable tablet Substances 0.000 description 4
- 235000005822 corn Nutrition 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000001850 reproductive effect Effects 0.000 description 4
- 239000006188 syrup Substances 0.000 description 4
- 235000020357 syrup Nutrition 0.000 description 4
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 3
- 244000215068 Acacia senegal Species 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 239000004375 Dextrin Substances 0.000 description 3
- 229920001353 Dextrin Polymers 0.000 description 3
- 239000004386 Erythritol Substances 0.000 description 3
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 229920000084 Gum arabic Polymers 0.000 description 3
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 239000004373 Pullulan Substances 0.000 description 3
- 229920001218 Pullulan Polymers 0.000 description 3
- 239000000205 acacia gum Substances 0.000 description 3
- 235000010489 acacia gum Nutrition 0.000 description 3
- 210000004404 adrenal cortex Anatomy 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 229910000389 calcium phosphate Inorganic materials 0.000 description 3
- 235000011010 calcium phosphates Nutrition 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 235000019425 dextrin Nutrition 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 235000013325 dietary fiber Nutrition 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 235000019414 erythritol Nutrition 0.000 description 3
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 3
- 229940009714 erythritol Drugs 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 235000015203 fruit juice Nutrition 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 235000001727 glucose Nutrition 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 235000014593 oils and fats Nutrition 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 235000019423 pullulan Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 238000002123 RNA extraction Methods 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 235000021552 granulated sugar Nutrition 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002493 microarray Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 description 1
- 101710159080 Aconitate hydratase A Proteins 0.000 description 1
- 101710159078 Aconitate hydratase B Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 101100189582 Dictyostelium discoideum pdeD gene Proteins 0.000 description 1
- 102100036334 Fragile X mental retardation syndrome-related protein 1 Human genes 0.000 description 1
- 101000930945 Homo sapiens Fragile X mental retardation syndrome-related protein 1 Proteins 0.000 description 1
- 101000828537 Homo sapiens Synaptic functional regulator FMR1 Proteins 0.000 description 1
- 206010028311 Muscle hypertrophy Diseases 0.000 description 1
- 101150098694 PDE5A gene Proteins 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 102000044126 RNA-Binding Proteins Human genes 0.000 description 1
- 101710105008 RNA-binding protein Proteins 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 102100023532 Synaptic functional regulator FMR1 Human genes 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000001780 adrenocortical effect Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 229960002749 aminolevulinic acid Drugs 0.000 description 1
- 235000013527 bean curd Nutrition 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 102100029175 cGMP-specific 3',5'-cyclic phosphodiesterase Human genes 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000002570 interstitial cell Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000002332 leydig cell Anatomy 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000012042 muscle hypertrophy Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000013324 preserved food Nutrition 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 210000002863 seminiferous tubule Anatomy 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000004034 viscosity adjusting agent Substances 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
本試験では、ヒト副腎皮質由来細胞 H295Rを5-アセチル-1-ベンジルピロリジン-2-オン存在下で培養した後 、DNAマイクロアレイ解析を実施し、FXR2遺伝子発現亢進作用があるか否かを確認した。
ヒト副腎皮質腺がん株(H295R)
American Type Culture Collection(ATCC)より入手。
1)5-アセチル-1-ベンジルピロリジン-2-オン10 mg にDMSO を100 μL 加え溶解し,DMSO で被験物質の濃度が50 mMとなるよう段階希釈した。
2)さらに細胞培養用培地で被験物質の濃度が50 μMとなるよう希釈した。
〈H295R細胞の調製〉
1)H295R 細胞を2×105 cell/mL の細胞濃度で6 cm dish に5 mLずつ播種した。
2)播種24 時間後に接着を確認し、細胞培養用培地を除去後、新たに被験物質(最終濃度50 μM)含有の細胞培養用培地を各5 mLずつ添加した。
3)添加後24 時間培養し、細胞培養用培地を抜いて接着細胞をPBS で洗浄後、得られた細胞を下述のRNA 抽出→DNA マイクロアレイ解析に用いた。
1)上述の細胞調製で得られた細胞から、RNAiso plus を用いてRNA を抽出し、RNeasy MinElute Cleanup Kitで精製した。
1)RNA サンプルをLow Input Quick Amp Labeling Kit (Agilent) を用いてcDNA の合成、Cy3 ラベル化cRNA 合成と精製を行った。
2)Gene Expression Hybridization Kit (Agilent) を用い、それぞれのラベル化cRNA をフラグメンテーションし,Whole Human Genome Microarray Ver2.0 (Agilent) にアプライ、65℃で17 時間ハイブリダイゼーションした。
3)Gene Expression Wash Buffer 1 及び2 (Agilent) を用い、アレイスライドを洗浄した。
4)マイクロアレイスキャナー (GenePix 4000B,Molecular Devices) でスキャンしたアレイ画像を、アレイ解析ソフトウェアGenePix Pro (Molecular Devices) で数値化した。蛍光強度値をノーマライズし、コントロールに対して被験物質添加群のRatioを算出した。
FXR2遺伝子は副腎皮質由来細胞(H295R)細胞において5-アセチル-1-ベンジルピロリジン-2-オン共存下で発現が1.76倍亢進した。よって、5-アセチル-1-ベンジルピロリジン-2-オンはFXR2遺伝子発現を亢進することでFXR2の産生を亢進すると考えられる。
Claims (2)
- 5-アセチル-1-ベンジルピロリジン-2-オンを有効成分として含有してなるFragile X mental retardation, autosomal homolog 2遺伝子発現亢進用医薬組成物。
- 5-アセチル-1-ベンジルピロリジン-2-オンを有効成分として含有してなるFragile X mental retardation, autosomal homolog 2遺伝子発現亢進用食品組成物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2023088851A JP7320898B1 (ja) | 2023-05-30 | 2023-05-30 | Fragile X mental retardation, autosomal homolog 2遺伝子発現亢進用医薬組成物及び食品組成物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2023088851A JP7320898B1 (ja) | 2023-05-30 | 2023-05-30 | Fragile X mental retardation, autosomal homolog 2遺伝子発現亢進用医薬組成物及び食品組成物 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP7320898B1 true JP7320898B1 (ja) | 2023-08-04 |
Family
ID=87474482
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023088851A Active JP7320898B1 (ja) | 2023-05-30 | 2023-05-30 | Fragile X mental retardation, autosomal homolog 2遺伝子発現亢進用医薬組成物及び食品組成物 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP7320898B1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7356203B1 (ja) | 2023-08-03 | 2023-10-04 | Towa Corporation 株式会社 | WD and tetratricopeptide repeats 1遺伝子発現亢進用医薬組成物及び食品組成物 |
JP7371996B1 (ja) | 2023-08-03 | 2023-10-31 | Towa Corporation 株式会社 | インスリン様成長因子2遺伝子発現亢進用医薬組成物及び食品組成物 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6537689B1 (ja) * | 2018-10-26 | 2019-07-03 | Towa Corporation 株式会社 | エストラジオール産生促進用医薬組成物及び食品組成物 |
JP2022184813A (ja) * | 2021-05-31 | 2022-12-13 | 高雄醫學大學 | マカ抽出物及びその用途 |
JP2022191536A (ja) * | 2019-11-27 | 2022-12-28 | 国立研究開発法人国立成育医療研究センター | サイトメガロウイルス関連疾患の予防又は治療用の剤 |
JP7253301B1 (ja) * | 2023-01-27 | 2023-04-06 | Towa Corporation 株式会社 | 5-アミノレブリン酸産生促進用医薬組成物及び食品組成物 |
-
2023
- 2023-05-30 JP JP2023088851A patent/JP7320898B1/ja active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6537689B1 (ja) * | 2018-10-26 | 2019-07-03 | Towa Corporation 株式会社 | エストラジオール産生促進用医薬組成物及び食品組成物 |
JP2022191536A (ja) * | 2019-11-27 | 2022-12-28 | 国立研究開発法人国立成育医療研究センター | サイトメガロウイルス関連疾患の予防又は治療用の剤 |
JP2022184813A (ja) * | 2021-05-31 | 2022-12-13 | 高雄醫學大學 | マカ抽出物及びその用途 |
JP7253301B1 (ja) * | 2023-01-27 | 2023-04-06 | Towa Corporation 株式会社 | 5-アミノレブリン酸産生促進用医薬組成物及び食品組成物 |
Non-Patent Citations (2)
Title |
---|
SYNTHETIC COMMUNICATIONS, vol. 28, no. 9, JPN6019017594, 1998, pages 1649 - 1659, ISSN: 0005105750 * |
Synthetic Communications,1998年,Vol.28, No.9,pp.1649-1659 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7356203B1 (ja) | 2023-08-03 | 2023-10-04 | Towa Corporation 株式会社 | WD and tetratricopeptide repeats 1遺伝子発現亢進用医薬組成物及び食品組成物 |
JP7371996B1 (ja) | 2023-08-03 | 2023-10-31 | Towa Corporation 株式会社 | インスリン様成長因子2遺伝子発現亢進用医薬組成物及び食品組成物 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7320898B1 (ja) | Fragile X mental retardation, autosomal homolog 2遺伝子発現亢進用医薬組成物及び食品組成物 | |
JP7253301B1 (ja) | 5-アミノレブリン酸産生促進用医薬組成物及び食品組成物 | |
JP7134541B1 (ja) | キサンチンオキシダーゼ阻害用医薬組成物及び食品組成物 | |
JP6578046B1 (ja) | Pde5阻害用医薬組成物及びpde5阻害用食品組成物 | |
JP6537689B1 (ja) | エストラジオール産生促進用医薬組成物及び食品組成物 | |
JP6962630B1 (ja) | 筋肥大促進用医薬組成物及び食品組成物 | |
AU2005320579B2 (en) | Sesamin/episesamin compositions | |
JP7311218B1 (ja) | アポリポタンパク質e遺伝子発現抑制用医薬組成物及び食品組成物 | |
JP7320897B1 (ja) | 脱共役タンパク2遺伝子発現亢進用医薬組成物及び食品組成物 | |
JP2011205913A (ja) | 機能性異性化糖の複合体結晶糖質およびその製造方法 | |
JP7002159B2 (ja) | 希少糖含有組成物の製造方法および希少糖含有組成物 | |
JP2007091631A (ja) | 抗ピロリ菌剤及びこれを含有する飲食物 | |
JPWO2019235142A1 (ja) | 結晶澱粉分解物、及び該結晶澱粉分解物を用いた飲食品用組成物、飲食品、医薬品、化粧料、工業製品、飼料、培地、肥料、及びこれらの改質剤、並びに、前記結晶澱粉分解物、飲食品用組成物、飲食品、医薬品、化粧料、工業製品、飼料、培地、及び肥料の製造方法 | |
JP6054020B2 (ja) | リジルオキシダーゼ活性を有する卵殻膜粉末 | |
WO2016047616A1 (ja) | 遅消化性持続型エネルギー補給剤 | |
JP7316017B1 (ja) | セレノプロテインo遺伝子発現亢進用医薬組成物及び食品組成物 | |
JP2023525663A (ja) | 苦味遮断薬および使用の関連方法 | |
JP7371996B1 (ja) | インスリン様成長因子2遺伝子発現亢進用医薬組成物及び食品組成物 | |
JP7356203B1 (ja) | WD and tetratricopeptide repeats 1遺伝子発現亢進用医薬組成物及び食品組成物 | |
JP7397541B1 (ja) | Nadh-ユビキノン酸化還元酵素サブユニット6遺伝子発現亢進用医薬組成物及び食品組成物 | |
JP7370653B1 (ja) | エリスロポエチン遺伝子発現亢進用医薬組成物及び食品組成物 | |
JP2009249322A (ja) | ペルオキシソーム増殖剤応答性受容体αおよびγ活性化剤 | |
US20210007980A1 (en) | Use of enzyme-modified isoquercitrin | |
WO2013172436A1 (ja) | クロシンの新規糖付加化合物、その製造方法、及びその用途 | |
JP2016190801A (ja) | 難消化性グルカンを含有する血中中性脂肪上昇抑制剤および血中レムナント様リポ蛋白コレステロール上昇抑制剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230530 |
|
A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20230530 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230711 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230718 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7320898 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |